Share Name Share Symbol Market Type Share ISIN Share Description
Silence Therapeutics Plc LSE:SLN London Ordinary Share GB00B9GTXM62 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.00 -0.45% 438.00 428.00 434.00 446.00 428.00 440.00 58,462 16:35:29
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -20.5 -26.2 - 342

Silence Therapeutics Share Discussion Threads

Showing 50451 to 50475 of 50950 messages
Chat Pages: Latest  2026  2025  2024  2023  2022  2021  2020  2019  2018  2017  2016  2015  Older
DateSubjectAuthorDiscuss
13/12/2018
15:55
Well that was a punt that's gone wrong, so far. Just clinging on in the hope that either the Quark results are good or a buyer appears, but the share price doesn't suggest it after the media rumours.
waterloo01
13/12/2018
12:45
& then how long to burn the cash? If they went for it a couple of years ??
djnzloop
13/12/2018
12:16
Cheaper by the day.......parity with net cash looms.......enterprise value zero?
soundbuy
10/12/2018
16:49
That was a nice jump from the low indeed
volsung
10/12/2018
16:45
volsung10 Dec '18 - 16:43 - 47665 of 47665 Need to go back to Jan 2012 to see a price lower than this. Low was around 57.5p. Hopefully be able to pick up a few at that price soon
buywell3
10/12/2018
16:43
Need to go back to Jan 2012 to see a price lower than this. Low was around 57.5p. Hopefully be able to pick up a few at that price soon
volsung
10/12/2018
16:37
buywell33 Aug '18 - 13:15 - 47557 of 47626 Edit Chartwise 75p seems possible
buywell3
10/12/2018
16:35
buywell3 - 24 Nov 2018 - 02:32:44 - 47636 of 47663 Silence Therapeutics (the old SR Pharma) - SLN You will be soon able to snap these up sub 70p according to Mr Chart It's a real bad one 70p gets bust and its the 2012 low next support Here it is
buywell3
10/12/2018
16:26
Bought some more at 71.68p. Av now 135.62
volsung
10/12/2018
13:46
Well at 72.5p and a market cap of £51.5m and with £37m in the bank, the enterprise value of the company is a ridiculously low £14.5m currently. A great buying opportunity for the patient value investor (or a predator!).
callumross
10/12/2018
12:14
Reflecting on the Peel Hunt note........ Whether that settlement was in the best interests of shareholders I'm none too sure.....thought they would have had a stronger hand to play.......... Hmmmm.......
soundbuy
10/12/2018
12:10
Bought a few more at 73.75p Av now 142.61p
volsung
10/12/2018
11:27
Peel Hunt comment H/T FT Alphaville We recognise that new management has never oversold the value of litigation (and we risk adjusted in our SOTP model) but that this outcome – whilst good news in putting ongoing risk and litigation cost behind us – is different to previous management’s communication of potential and our assumptions in the model (including £10m milestone and estimated royalties of 2-5%). This is validation of Silence’s expertise in the RNAi chemistry. New management is much more focused on pipeline and expects to build this out in the near future and is well capitalised for this (PHe 2018E of c£37m cash prior to adjusting for the milestones/todays news). Further terms of the agreement include the grant from Silence to Alnylam of a non-exclusive, global irrevocable, license to all relevant patents and for all current and future Alnylam products (whether commercialised by Alnylam, a collaborator or a licensee). Under this agreement, all ongoing court proceedings will now be dismissed. We will review with new management and temporarily move to U/R – we will update our model in due course, in order to assess new management’s perspective on timelines and indications now that litigation is out of the way. Future news flow – with the sensitivities of litigation now behind us, the company will now be able to focus on applying its RNAi expertise to the pipeline. In the near- to medium-future, we believe the company is likely to be able to update on: • The outcome of sub-licensed IP to Quark (partnered with Novartis) for QPI1002 (currently Phase 3), where SLN are eligible for c1-4% royalties or c15% of clinical/commercial milestone payments. • Developments in SLN’s pipeline for new and existing assets. The lead candidate SLN124 for beta-thalassaemia, with CTA planned for H1 2019).
soundbuy
10/12/2018
11:26
So suggested that it was Amicus that was looking at SLN. Does this clear the way and why they settled?
waterloo01
10/12/2018
11:16
Reactions a bit OTT. Guess many expecting a better outcome from trial. I'll stick around for a bit on hopes for take-over, now this is out the way. Quark results due shortly: QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant (ReGIFT). Results due December 18
waterloo01
10/12/2018
10:25
News went down well then..............
soundbuy
10/12/2018
08:36
The grant of the licence for all other future Alnylam products presumably includes an undisclosed one off payment. "Terms of the settlement, which includes no admissions by any party, are otherwise confidential."
callumross
10/12/2018
08:34
It does look like a decent deal for Alny, less so for SLN but it does reinforce the patent and might lead to some corporate action?
waterloo01
10/12/2018
08:26
Looks to me like a pretty good outcome for Alny. Do others see it differently? "Further terms of the agreement include the grant from Silence to Alnylam of a non-exclusive, global irrevocable, license to all relevant patents and for all current and future Alnylam products, whether commercialized by Alnylam or a collaborator or licensee (including ONPATTRO, vutrisiran, givosiran, lumasiran, inclisiran, fitusiran, cemdisiran, ALN-HBV02, ALN-AAT02, and all other investigational therapeutics in Alnylam’s current and future pipeline). Such license is fully paid up with no milestones or royalties, except for the limited royalty on ONPATTRO net sales in the EU described above. " hTtp://investors.alnylam.com/news-releases/news-release-details/alnylam-announces-settlement-litigation-silence-therapeutics
1gw
10/12/2018
07:46
If there's a potential acquirer out there this removes the uncertainty
soundbuy
10/12/2018
07:25
The mostly likely (and sensible) outcome.......
soundbuy
10/12/2018
07:23
So a deal done before the trial.
waterloo01
10/12/2018
07:19
Deal then, but with limits on geographic scope, duration and magnitude of royalty. Maybe some further value as a precedent for other potential drugs?
1gw
07/12/2018
16:37
So, settlement talks over the weekend, in court on Monday if no deal reached? Doesn't look like the market's expecting sln to come out on top.
1gw
04/12/2018
10:22
Hi Callumross,do you know what the "AMENDED COMPLAINT" judgement means.
tshirley12
Chat Pages: Latest  2026  2025  2024  2023  2022  2021  2020  2019  2018  2017  2016  2015  Older
Your Recent History
LSE
SLN
Silence Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191122 18:07:41